HC Wainwright Issues Pessimistic Outlook for RCUS Earnings

Arcus Biosciences, Inc. (NYSE:RCUS - Free Report) - Equities research analysts at HC Wainwright cut their Q2 2025 earnings estimates for shares of Arcus Biosciences in a research report issued to clients and investors on Wednesday, May 7th. HC Wainwright analyst E. Bodnar now anticipates that the company will post earnings per share of ($1.19) for the quarter, down from their prior forecast of ($0.93). HC Wainwright has a "Buy" rating and a $24.00 price objective on the stock. The consensus estimate for Arcus Biosciences' current full-year earnings is ($3.15) per share. HC Wainwright also issued estimates for Arcus Biosciences' Q3 2025 earnings at ($1.24) EPS, Q4 2025 earnings at ($1.27) EPS, FY2025 earnings at ($5.04) EPS, FY2026 earnings at ($5.54) EPS, FY2027 earnings at ($5.30) EPS, FY2028 earnings at ($2.83) EPS and FY2029 earnings at ($1.63) EPS.

Arcus Biosciences (NYSE:RCUS - Get Free Report) last announced its earnings results on Tuesday, May 6th. The company reported ($1.14) EPS for the quarter, missing analysts' consensus estimates of ($1.02) by ($0.12). Arcus Biosciences had a negative return on equity of 45.59% and a negative net margin of 102.66%. The company had revenue of $28.00 million during the quarter, compared to analysts' expectations of $38.61 million. During the same quarter last year, the firm posted ($0.05) EPS. Arcus Biosciences's revenue for the quarter was down 80.7% compared to the same quarter last year.

RCUS has been the topic of several other research reports. Barclays dropped their price objective on Arcus Biosciences from $29.00 to $14.00 and set an "overweight" rating on the stock in a research note on Wednesday, April 23rd. The Goldman Sachs Group lowered their price target on Arcus Biosciences from $15.00 to $13.00 and set a "neutral" rating for the company in a report on Thursday. Bank of America reduced their price objective on Arcus Biosciences from $22.00 to $17.00 and set a "neutral" rating for the company in a research note on Wednesday, February 19th. Wedbush reaffirmed an "outperform" rating and set a $33.00 target price on shares of Arcus Biosciences in a report on Wednesday, May 7th. Finally, Morgan Stanley decreased their price objective on shares of Arcus Biosciences from $24.00 to $22.00 and set an "overweight" rating for the company in a research report on Friday. Two research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $25.67.

Arcus Biosciences Trading Up 6.5%

Shares of RCUS stock traded up $0.54 on Friday, reaching $8.82. 2,674,579 shares of the company's stock were exchanged, compared to its average volume of 835,966. The stock has a market capitalization of $933.38 million, a PE ratio of -2.80 and a beta of 0.88. Arcus Biosciences has a 52 week low of $6.50 and a 52 week high of $18.98. The company has a current ratio of 5.24, a quick ratio of 5.24 and a debt-to-equity ratio of 0.08. The company's fifty day simple moving average is $8.38 and its 200 day simple moving average is $12.30.

Institutional Trading of Arcus Biosciences

Large investors have recently made changes to their positions in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in Arcus Biosciences by 2.5% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 34,007 shares of the company's stock worth $506,000 after acquiring an additional 833 shares during the period. JPMorgan Chase & Co. grew its position in shares of Arcus Biosciences by 2.6% in the third quarter. JPMorgan Chase & Co. now owns 43,685 shares of the company's stock valued at $668,000 after purchasing an additional 1,117 shares during the last quarter. R Squared Ltd purchased a new stake in shares of Arcus Biosciences in the fourth quarter valued at $26,000. Maryland State Retirement & Pension System boosted its stake in shares of Arcus Biosciences by 10.9% during the 1st quarter. Maryland State Retirement & Pension System now owns 20,202 shares of the company's stock worth $159,000 after purchasing an additional 1,986 shares during the last quarter. Finally, Teacher Retirement System of Texas raised its holdings in Arcus Biosciences by 19.2% in the 4th quarter. Teacher Retirement System of Texas now owns 14,952 shares of the company's stock valued at $223,000 after acquiring an additional 2,410 shares during the last quarter. 92.89% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In related news, Director Yasunori Kaneko acquired 20,000 shares of the firm's stock in a transaction dated Thursday, February 27th. The stock was acquired at an average price of $10.06 per share, for a total transaction of $201,200.00. Following the purchase, the director now owns 28,400 shares of the company's stock, valued at $285,704. This represents a 238.10% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Terry J. Rosen purchased 19,800 shares of the stock in a transaction that occurred on Thursday, February 27th. The stock was acquired at an average cost of $10.18 per share, with a total value of $201,564.00. Following the completion of the acquisition, the chief executive officer now directly owns 2,554,160 shares of the company's stock, valued at $26,001,348.80. This represents a 0.78% increase in their ownership of the stock. The disclosure for this purchase can be found here. Corporate insiders own 12.30% of the company's stock.

Arcus Biosciences Company Profile

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.